Free Trial

Pfizer (PFE) Stock Price, News & Analysis

Pfizer logo
$25.96 +0.09 (+0.33%)
Closing price 05/13/2026 03:59 PM Eastern
Extended Trading
$25.98 +0.03 (+0.10%)
As of 06:55 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

About Pfizer Stock (NYSE:PFE)

Advanced

Key Stats

Today's Range
$25.64
$26.09
50-Day Range
$25.65
$28.56
52-Week Range
$21.97
$28.75
Volume
39.37 million shs
Average Volume
36.72 million shs
Market Capitalization
$147.93 billion
P/E Ratio
19.81
Dividend Yield
6.63%
Price Target
$28.74
Consensus Rating
Hold

Company Overview

Pfizer Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
77th Percentile Overall Score

PFE MarketRank™: 

Pfizer scored higher than 77% of companies evaluated by MarketBeat, and ranked 157th out of 864 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Pfizer has received a consensus rating of Hold. The company's average rating score is 2.23, and is based on 1 strong buy rating, 6 buy ratings, 12 hold ratings, and 3 sell ratings.

  • Upside Potential

    Pfizer has a consensus price target of $28.74, representing about 10.7% upside from its current price of $25.96.

  • Amount of Analyst Coverage

    Pfizer has been the subject of 13 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Pfizer's stock forecast and price target.
  • Earnings Growth

    Earnings for Pfizer are expected to decrease by -4.03% in the coming year, from $2.98 to $2.86 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Pfizer is 19.81, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 44.35.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Pfizer is 19.81, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 20.99.

  • Price to Book Value per Share Ratio

    Pfizer has a P/B Ratio of 1.64. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    2.48% of the float of Pfizer has been sold short.
  • Short Interest Ratio / Days to Cover

    Pfizer has a short interest ratio ("days to cover") of 4.01.
  • Change versus previous month

    Short interest in Pfizer has recently increased by 5.17%, indicating that investor sentiment is decreasing significantly.
  • Dividend Leadership

    Pfizer is a leading dividend payer. It pays a dividend yield of 6.65%, putting its dividend yield in the top 25% of dividend-paying stocks.

  • Dividend Growth

    Pfizer has been increasing its dividend for 16 years.

  • Dividend Coverage

    The dividend payout ratio of Pfizer is 131.30%. Payout ratios above 75% are not desirable because they may not be sustainable.

  • Dividend Sustainability

    Based on earnings estimates, Pfizer will have a dividend payout ratio of 60.14% next year. This indicates that Pfizer will be able to sustain or increase its dividend.

  • Read more about Pfizer's dividend.
  • News Sentiment

    Pfizer has a news sentiment score of 0.79. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.62 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 73 news articles for Pfizer this week, compared to 13 articles on an average week.
  • Search Interest

    234 people have searched for PFE on MarketBeat in the last 30 days. This is an increase of 46% compared to the previous 30 days.
  • MarketBeat Follows

    118 people have added Pfizer to their MarketBeat watchlist in the last 30 days. This is an increase of 307% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Pfizer insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    0.62% of the stock of Pfizer is held by insiders.

  • Percentage Held by Institutions

    68.36% of the stock of Pfizer is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Pfizer's insider trading history.
Receive PFE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Pfizer and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

PFE Stock News Headlines

4 stocks to watch on Wednesday: BABA, PFE, TWO, NBIS
Read this warning immediately
Porter Stansberry, founder of one of the world's largest financial research firms, says he's breaking the biggest story of his 26-year career. A famous historian whose books have sold over 45 million copies in 65 languages is warning of a structural shift so large it has only one historical parallel - 1776. One Stanford economist calls it 'the biggest change ever - bigger than electricity, bigger than the steam engine.' Stansberry outlines the stocks to buy, the stocks to sell, and three money moves to position yourself on the right side of this shift.tc pixel
Top Analyst Reports for Meta, Pfizer & Salesforce
Can Pfizer Achieve High Single-Digit Revenue CAGR From 2029?
See More Headlines

PFE Stock Analysis - Frequently Asked Questions

Pfizer's stock was trading at $24.90 at the start of the year. Since then, PFE stock has increased by 4.2% and is now trading at $25.9550.

Pfizer Inc. (NYSE:PFE) issued its quarterly earnings results on Tuesday, May, 5th. The biopharmaceutical company reported $0.75 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.72 by $0.03. Pfizer's revenue was up 5.4% on a year-over-year basis.
Read the conference call transcript
.

Pfizer subsidiaries include ReViral, Arena, Trillium Therapeutics, Amplyx Pharmaceuticals, Array BioPharma, Therachon, Medivation, and others.

Top institutional investors of Pfizer include Bank of New York Mellon Corp (0.95%), Dimensional Fund Advisors LP (0.64%), First Trust Advisors LP (0.36%) and Swiss National Bank (0.29%). Insiders that own company stock include Ronald E Blaylock and Scott Gottlieb.
View institutional ownership trends
.

Shares of PFE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Pfizer investors own include Scilex (SCLX), Salesforce (CRM), Chevron (CVX), AbbVie (ABBV), Johnson & Johnson (JNJ), Meta Platforms (META) and Bristol Myers Squibb (BMY).

Company Calendar

Record date for 3/6 Dividend
1/23/2026
Ex-Dividend for 3/6 Dividend
1/23/2026
Dividend Payable
3/06/2026
Last Earnings
5/05/2026
Record date for 6/12 Dividend
5/08/2026
Ex-Dividend for 6/12 Dividend
5/08/2026
Today
5/13/2026
Dividend Payable
6/12/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NYSE
Sector
Medical
Industry
Large Cap Pharma
Sub-Industry
Pharmaceuticals
Current Symbol
NYSE:PFE
CIK
78003
Employees
75,000
Year Founded
1849

Price Target and Rating

High Price Target
$36.00
Low Price Target
$24.00
Potential Upside/Downside
+10.7%
Consensus Rating
Hold
Rating Score (0-4)
2.23
Research Coverage
22 Analysts

Profitability

EPS (Trailing Twelve Months)
$1.31
Trailing P/E Ratio
19.81
Forward P/E Ratio
8.71
P/E Growth
N/A
Net Income
$7.77 billion
Net Margins
11.83%
Pretax Margin
12.48%
Return on Equity
19.44%
Return on Assets
8.41%

Debt

Debt-to-Equity Ratio
0.67
Current Ratio
1.25
Quick Ratio
0.94

Sales & Book Value

Annual Sales
$62.58 billion
Price / Sales
2.36
Cash Flow
$4.41 per share
Price / Cash Flow
5.88
Book Value
$15.86 per share
Price / Book
1.64

Miscellaneous

Outstanding Shares
5,699,440,000
Free Float
5,664,107,000
Market Cap
$147.93 billion
Optionable
Optionable
Beta
0.35

Social Links

 The Best Nuclear Energy Stocks to Buy Cover

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report

This page (NYSE:PFE) was last updated on 5/14/2026 by MarketBeat.com Staff.
From Our Partners